| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 March 2011 |
The treatment of chronic hepatitis B in adults with cirrhosis, including those with liver decompensation is included in the scope of the Clinical Guideline Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults. Therefore, the appraisal of entecavir and tenofovir disoproxil fumarate for the treatment of chronic hepatitis B in adults with decompensated liver disease has been un-referred from the NICE technology appraisal work programme. |
| 8 March 2011 |
Following the additional draft scope consultation, further discussions with the Department of Health and noting the overlap between the Technology Appraisal and the recently referred Clinical Guideline; The diagnosis and management of hepatitis B in children, adolescents and adults, it has been decided that the Technology Appraisal will be suspended until the outcome of the scoping process for the Clinical Guideline is known.
|
| 6 May 2010 |
Please note that this appraisal is now expected to start inapproximately early December 2010. The deadline for submissions is expectedin approximately late March 2011. |
For further information on our processes and methods, please see our CHTE processes and methods manual